PROTHENA CORP PUBLIC LTD CO, commonly known as Prothena, is publicly traded under the ticker symbol PRTA. It is a biotechnological company that predominantly focuses on the discovery, development, and commercialization of novel therapies designed to combat life-threatening diseases in the field of neuroscience. Prothena is specifically committed to targeting proteins dysfunctions that may lead to devastating neurodegenerative conditions.
The company was established with a vision to establish transformative therapies for patients with neurodegenerative disorders and initiate a new wave of effective treatments for these debilitating diseases. The diseases targeted by Prothena’s research are often associated with abnormal deposition of misfolded proteins, such as Parkinson’s and Alzheimer’s diseases, Amyotrophic Lateral Sclerosis (ALS), and Peripheral Neuropathy.
Prothena's portfolio includes a diverse range of therapeutic antibodies, made possible by its proprietary discovery engine and approach to protein dysfunctions. One of its lead pipeline candidates, PRX002/RG7935, targets the alpha-synuclein protein associated with Parkinson's disease and is being developed in collaboration with the global biopharmaceutical company, Roche.
The company strives to improve patient outcomes and the quality of life for those affected by neurodegenerative diseases, and it underscores the importance of innovation and scientific discovery. Prothena’s team comprises a broad range of scientific and clinical experts who utilise their aptitudes to create life-changing treatments.
Prothena is based in Dublin, Ireland, but has expanded to have a significant presence in the United States, specifically in the San Francisco Bay Area. As a public limited company (PLC), Prothena shares are floated on public exchanges, enabling investors to buy in and support the company's ambitions and progress.
Beyond its commitment to innovative R&D, Prothena values strong corporate governance and is dedicated to operating with integrity. This includes adhering to strict ethical guidelines, managing resources wisely, and being transparent with investors and stakeholders.
In summary, Prothena Corp Public Ltd Co is an innovative biotechnology firm committed to creating transformative therapies for serious and often rare neurodegenerative diseases. Its extensive research, strategic collaborations, and dedication to integrity play a part in its steadfast journey towards its vision of improving the lives of patients by easing the burdens they face.